

Cite this: *Chem. Sci.*, 2024, 15, 9649 All publication charges for this article have been paid for by the Royal Society of Chemistry

Employing unnatural promiscuity of sortase to construct peptide macrocycle libraries for ligand discovery†

Yan-Ni Zhang,^{‡a} Xiao-Cui Wan,^{‡a} Yang Tang,^{‡b} Ying Chen,^a Feng-Hao Zheng,^a Zhi-Hui Cui,^a Hua Zhang,^a Zhaocai Zhou^c and Ge-Min Fang^{id}*^a

With the increasing attention paid to macrocyclic scaffolds in peptide drug development, genetically encoded peptide macrocycle libraries have become invaluable sources for the discovery of high-affinity peptide ligands targeting disease-associated proteins. The traditional phage display technique of constructing disulfide-tethered macrocycles by cysteine oxidation has the inherent drawback of reduction instability of the disulfide bond. Chemical macrocyclization solves the problem of disulfide bond instability, but the involved highly electrophilic reagents are usually toxic to phages and may bring undesirable side reactions. Here, we report a unique Sortase-mediated Peptide Ligation and One-pot Cyclization strategy (SPLOC) to generate peptide macrocycle libraries, avoiding the undesired reactions of electrophiles with phages. The key to this platform is to mine the unnatural promiscuity of sortase on the X residue of the pentapeptide recognition sequence (LPXTG). Low reactive electrophiles are incorporated into the X-residue side chain, enabling intramolecular cyclization with the cysteine residue of the phage-displayed peptide library. Utilizing the genetically encoded peptide macrocycle library constructed by the SPLOC platform, we found a high-affinity bicyclic peptide binding TEAD4 with a nanomolar KD value (63.9 nM). Importantly, the binding affinity of the bicyclic peptide ligand is 102-fold lower than that of the acyclic analogue. To our knowledge, this is the first time to mine the unnatural promiscuity of ligases to generate peptide macrocycles, providing a new avenue for the construction of genetically encoded cyclic peptide libraries.

Received 26th March 2024
Accepted 11th May 2024

DOI: 10.1039/d4sc01992j

rsc.li/chemical-science

Introduction

Peptide macrocycles are attractive scaffolds for peptide drug development.^{1,2} Many peptide drugs entering clinical trials are peptide macrocycles.³ In comparison with linear peptides, peptide macrocycles exhibit many favorable pharmacological properties, such as increased affinity for targets, enhanced cell membrane permeability and increased resistance to proteolysis. Additionally, peptide macrocycles have a larger surface than small molecules and are perceived to be more suitable for targeting protein–protein interactions.^{4–6} Currently, techniques for generating large-scale peptide macrocycle libraries include creating synthetic combinatorial chemical libraries and

genetically encoded peptide libraries.^{7,8} Genetically encoded peptide libraries, such as phage display and mRNA display, can easily provide a diversity of 10⁹–10¹² and they are an invaluable avenue for discovering high-affinity peptide ligands.⁹ New macrocyclization strategies on phage-displayed peptide libraries will expand the structural diversity of genetically encoded libraries and facilitate the discovery of macrocyclic peptide drugs.

Traditional phage-displayed peptide macrocycle libraries are disulfide-tethered cyclic peptides formed by cysteine oxidation at several fixed positions.^{10–16} However, the disulfide bonds are easily exchanged with free sulfhydryl groups and are unstable in reducing environments.^{17–19} In order to solve this problem, many chemical macrocyclization methods for phage libraries have been developed.^{20–22} Among them, one of the most widely used approaches is the use of electrophilic reagents to crosslink two or more Cys residues to construct thioether-tethered peptide monocycles or peptide bicycles.^{23–36} To ensure the efficiency of the macrocyclization reactions, phage libraries are often treated with highly reactive electrophilic reagents such as benzyl bromide derivatives, which sometimes cause undesired side reactions and phage toxicity.^{23,28,29} The embedding of orthogonal reactive non-canonical amino acids (UAAs) is an

^aSchool of Life Sciences, Institutes of Physical Science and Information Technology, Anhui University, Hefei 230601, P. R. China. E-mail: fanggm@ahu.edu.cn^bDepartment of Medical Ultrasound, Department of Stomatology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, Tongji University School of Medicine, Shanghai 200072, P. R. China^cState Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai 200438, P. R. China† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4sc01992j>

‡ These authors contributed equally.






Fig. 2 SrtA-mediated ligation and one-pot cyclization (SPLOC). (A) SrtA-mediated ligation and cyclization of pentapeptides with N-terminal glycine peptide 2 to generate the desired monocyclic products. (B) SrtA-mediated ligation and cyclization of pentapeptide 8 with N-terminal glycine peptide 9 to generate bicyclic products of two different scaffolds. (C) SrtA-mediated ligation and cyclization of pentapeptides with N-terminal glycine peptide 9 to generate the desired bicyclic products. (D) HPLC chromatograms (210 nm) of SrtA-mediated ligation and cyclization of 1 with an equivalent amount of 2 (# denotes an uncyclized ligation intermediate; a trace amount of SrtA-mediated hydrolysis of 1 could be observed in the mass spectrum of 3 as indicated by the asterisk). (E) HPLC chromatograms (210 nm) of SrtA-mediated ligation and cyclization of 9 with an equivalent amount of 10. (F) HPLC chromatograms (210 nm) of SrtA-mediated ligation and cyclization of 9 with an equivalent amount of 14. Reaction conditions: 50 μ M peptides, 5 μ M SrtA, 50 mM HEPES, 100 mM NaCl, 2 mM CaCl_2 , and 1 mM TCEP, pH 7 or pH 8, 37 $^\circ\text{C}$. Note that the desired macrocyclic peptide product was formed upon addition of SrtA.

not recognized by SrtA. The resistance of 3 to SrtA-mediated hydrolysis would be beneficial to the utility of the SPLOC strategy in the construction of peptide macrocycles.

The conventional sortase-catalyzed peptide ligation is reversible, and the peptide substrate cannot be completely converted into the ligation product (Fig. S32[†]).^{57–59} The product of the conventional sortase-catalyzed ligation can also be hydrolyzed by SrtA.⁶⁰ We speculated that SrtA does not recognize the cyclic peptide product, and therefore 3 formed by the SPLOC strategy could not be hydrolyzed by SrtA, resulting in irreversible enzymatic ligation of 1 and 2. The ligation of 1 and 2 was completed in 10 minutes, followed by the cyclization between the chloroacetyl group and the cysteine residue. Note that, in the absence of SrtA, the reaction between 1 and 2 did not proceed (ESI, Fig. S32[†]), demonstrating that peptide ligation and macrocyclization occurred under the catalysis of SrtA.

Given the previously reported SrtA-mediated irreversible ligation of depsiptides or thioester peptides with N-terminal

glycine peptides,^{57,59} we investigated the reaction of the depsiptide 4 or the thioester peptide 5 with 2. As expected, upon addition of SrtA, both 4 and 5 react with 2 to generate the desired 3 (ESI, Fig. S33–S34[†]). In the absence of SrtA, 5 and 2 undergo thioester–thiol exchange to form a thioester-linked byproduct (ESI, Fig. S34[†]).⁶¹ Because of the presence of many cysteine residues in pIII protein, 5 may not be ideal for phage modification. In contrast, 1 and 4 are inert toward thiols in neutral aqueous buffers and therefore are ideal for phage modification.

We further investigated the substrate scope of the SrtA-mediated peptide cyclization for the N-terminal glycine peptide. The arginine residue following the N-terminal glycine residue of 2 was replaced by other natural L-amino acids (except cysteine), resulting in 18 N-terminal glycine peptides. Among these amino acid mutants, 17 mutant peptides (except proline) underwent SrtA-mediated ligation and one-pot cyclization (ESI, Fig. S37–S54[†]) to generate the desired monocyclic products. Of



note, we observed the hydrolysis of **1** catalyzed by sortase A and the appearance of some small peaks after SrtA-mediated ligation and one-pot cyclization. These small peaks are mainly the hydrolysis by-product of **1** and the remaining peptide substrates. SrtA-mediated hydrolysis of **1** may have little effect on the modification of the phage-displayed libraries because the amount of **1** is in large excess relative to the phage particles. Additionally, we replaced ^{ClAc}Lys of **1** with ^{ClAc}Dap to obtain **6** (Dap: diaminopropionic acid). The relatively short side chain of Dap may increase the structural rigidity of the formed peptide macrocycles. To our delight, the enzymatic ligation and peptide cyclization of **2** and **6** was completed in one hour, yielding the desired cyclic peptide **7** (ESI, Fig. S35†). Collectively, these results demonstrate that the X site of the LPXTG motif can be unnatural amino acids that contain an electrophilic group, and the electrophilic group can be employed for peptide monocyclization.

Sortase-mediated peptide ligation and bicyclization

We next explored SrtA-mediated peptide bicyclization. The N-terminal amino group of **1** was modified with a chloroacetyl group to afford **8** (Fig. 2B). As expected, upon addition of SrtA, **8** reacted with **9** containing two cysteine residues to form bicyclic peptides. Due to the asymmetry of the chloroacetyl groups in **8**, we observed the formation of two bicyclic peptides with the same molecular weight (Fig. 2B, ESI, Fig. S55†). The resultant two bicyclic scaffolds can expand the structural diversity of phage libraries,²⁶ but would increase the workload of identifying bicyclic peptide ligands. To solve this problem, 3,5-bis(2-chloroacetamido)benzoic acid (Cab) was anchored onto the lysine residue of **1** to generate **10** (Fig. 2C). The twofold symmetry of the Cab group ensures the formation of one product. Indeed, **10** reacts with **9** to yield the desired bicyclic peptide **11** (Fig. 2E).

Meanwhile, we studied the enzymatic ligation between depsipeptide **13** and **9**. Expectedly, **13** reacts with **9** to give the desired **11** (ESI, Fig. S57†). To fine-tune the topological structure of the bicyclic scaffold, we replaced Lys in **10** with Dap to generate **14**. Gratifyingly, ligation and one-pot cyclization between **14** and **9** proceeded smoothly to generate the desired **12** (Fig. 2F). In addition, we replaced Cab in **13** with the 1,3-dibromo-methyl benzyl group (Bmb). Although the Bmb analogue of **14** reacts with **9** smoothly to provide the desired bicyclic peptide (ESI, Fig. S59–S60†), TCEP can react with the bromomethylbenzyl moiety.⁶² During the modification of phage-displayed libraries, this side reaction can be avoided. Specifically, the phage-displayed libraries are first treated with TCEP so that cysteine residues on the phage surface do not form disulfide bonds, and then the excess TCEP is removed by ultrafiltration or PEG precipitation. With the TCEP-treated phage libraries, we could perform sortase-mediated peptide ligation and bicyclization by using the Bmb analogue of **14**. It should be noted that, compared to **14**, the operation process for the Bmb analogue of **14** is relatively time-consuming.

Sortase-mediated modification of phage display libraries

Encouraged by the success of SrtA-mediated peptide ligation and one-pot cyclization (SPLOC), we decided to combine the

SPLOC-based strategy with phage display (Fig. 3A and B). First, we investigated the influence of SrtA-based reaction conditions on phage infectivity. Starting from the M13KE phage vector, a peptide library of GX₁₂C (X is any L-amino acid) was fused to the N-terminus of pIII protein, and a flexible linker (GGSGGSGG) was inserted between pIII protein and the peptide library. After electroporation of the engineered phage vector to cells, a phage library with a diversity of 10⁶ was obtained. To our delight, SrtA and **1** had little effect on the infectivity of the M13KE phage (Fig. 3C). Then, a biotin-avidin pull-down assay was performed to evaluate the efficacy of SrtA-mediated peptide ligation on the phage surface. **Biotin-1** was synthesized by coupling biotin to the N-terminal amino group of **1**. The phages were dissolved in 50 mM HEPES buffer (100 mM NaCl, 2 mM CaCl₂, 1 mM TCEP, pH8) and treated with **Biotin-1** (50 μM) for one hour at 25 °C. After pulldown with avidin-coated beads, about 73% of phages were captured (ESI, Fig. S85†), indicating the yield of SrtA-mediated peptide ligation on the phage surface.⁶³ It should be noted that sortase-mediated phage surface modification has been thoroughly demonstrated in previous studies.^{64–68} As a control, the amount of phage particles without **Biotin-1** treatment showed little change before and after biotin capture. Although the biotin capture assay cannot assess the following peptide cyclization, the intramolecular reaction between the chloroacetyl group and cysteine residue has proven to be rapid and efficient in many previous studies.^{23–36}

Selection of peptide monocycles targeting TEAD4. We finally used the SrtA-based phage display to screen for cyclic peptide ligands targeting TEAD4. TEAD4, a transcription factor that regulates cell proliferation and organ development by interacting with YAP/TAZ, is a potential target for tumor therapy.^{69,70} To obtain a large peptide library, we chose a phagemid system consisting of the pCantab 5E vector and M13KO7 helper phage. A peptide library of GX₁₂C was fused to the N-terminus of the pIII protein. By electroporating the engineered pCantab 5E vector into TG1 cells, we obtained a phage library with a diversity of 4 × 10⁶. The phage library was treated with **1** and SrtA in the presence of TCEP (1 mM). The resultant cyclic peptides were panned against immobilized TEAD4. After four rounds of selection, phage recovery increased 102 times compared with the first round (Fig. 3D). Surprisingly, sequencing 30 individual colonies picked at random revealed only one peptide. To avoid false positives, we randomly selected 19 colonies from the third round, 17 of which had the same sequence as the fourth round, indicating that the enriched peptide is likely to be a ligand for TEAD4.

We chose to synthesize the enriched peptide **15** (Fig. 3E and F), and measure its affinity to TEAD4. The dissociation constant (*K_D*) of **15** to TEAD4 was measured to be 2.1 μM in the fluorescence polarization assay (Fig. 3H). In a competition experiment with YAP, **15** inhibited 50% of TEAD4·YAP interaction with an apparent EC₅₀ of 8.9 μM (Fig. 3K). For comparison, the linear version of **15** shows a *K_D* value of 6.3 μM for TEAD4 (ESI, Fig. S79†). To study the influence of the cyclic peptide scaffold on phage biopanning, we used **6** containing ^{ClAc}Dap (Fig. 2A) to treat the phage library to generate structurally more rigid






Fig. 3 SrtA-mediated phage display of macrocyclic peptides against TEAD4. (A) Scheme for the SrtA-based phage display (SAV: streptavidin-coated beads). (B) Construction of a monocyclic peptide library (M-library) and bicyclic peptide library (B-library) by SrtA-mediated peptide cyclization on the phage surface; M(1)-library is a monocyclic peptide library constructed by macrocyclization of the phage displayed GX₁₂C library with **1**; B(10)-library is a bicyclic peptide library constructed by the macrocyclization of the phage-displayed GX₆CX₆C library with **10**. (C) Influence of different buffers on the infectivity of M13KE phages. Buffer 1: PBS (pH 7.4); buffer 2: 50 mM HEPES, 100 mM NaCl, 2 mM CaCl₂, 1 mM TCEP, pH 8; buffer 3: 50 mM HEPES, 100 mM NaCl, 2 mM CaCl₂, 1 mM TCEP, 5 μM SrtA, pH 8; buffer 4: 50 mM HEPES, 100 mM NaCl, 2 mM CaCl₂, 1 mM TCEP, 50 μM peptide **1**, pH 8; buffer 5: 50 mM HEPES, 100 mM NaCl, 2 mM CaCl₂, 1 mM TCEP, 5 μM SrtA, 50 μM peptide **1**, pH 8. (D) Phage titers after 3–4 rounds of selection against immobilized TEAD4 (R3' and R4' are negative selections with solely avidin-coated beads). (E) Enriched peptide sequences after phage display screening targeting TEAD4; B(14)-library is a bicyclic peptide library constructed by macrocyclization of the phage-displayed GX₆CX₆C library with **14**. (F) and (G) Chemical structure of **15** and **16** from the phage biopanning of the M-library and B-library. (H), (I) and (J) Binding affinity of **15**, **16** and **18** to TEAD4 measured by the fluorescence polarization method. (K) and (L) Inhibition of TEAD4·YAP by **15** or **16** assessed by the fluorescence polarization assay.

cyclopeptides. After four rounds of biopanning, phage recovery was only 4-fold higher than in the first round, much lower than that of the phage treated with **1**. The observed differences in phage enrichment suggest that the chemical bridge may

profoundly affect the result of biopanning.²⁷ Note that, in our platform, different chemical bridges can be easily introduced at the X site of the LPXTG motif to increase the likelihood of finding the ideal peptide ligands.



Selection of peptide bicycles targeting TEAD4. We then designed a phage library of bicyclic peptides to screen for TEAD4-binding peptide bicycles. The library of GX_6CX_6C was inserted into the N-terminus of pIII protein, generating a phage library with a diversity of 2×10^8 . After treatment with SrtA and **10**, phage biopanning was performed against immobilized TEAD4. After three rounds of selection, the phage recovery increased by 14 times (Fig. 3D). Note that the number of phages eluted from TEAD4-bound beads was 139-fold higher than that eluted from solely avidin-coated beads. Ten phage colonies were randomly picked for DNA sequencing. Surprisingly, all the colonies were decoded to the same peptide sequence. Meanwhile, we treated the phage with **14** containing Cab Dap to generate bicyclic peptides with a different topology (Fig. 2C). The enrichment factors from four rounds of screening indicate selection favoring TEAD4 protein (ESI, Fig. S87[†]), and 39 phage colonies were randomly selected for sequencing (ESI, Fig. S89–S90[†]).

We synthesized five bicyclic peptides for K_D value measurement. Among them, **16** (Fig. 3G) was identified as a good ligand for TEAD4 with a K_D value of 63.9 nM (Fig. 3I), superior to the other four bicyclic peptides (Fig. 3E and J). As expected, **16** exhibited concentration-dependent inhibition of TEAD4·YAP interaction with an EC_{50} of 0.67 μ M (Fig. 3L). Moreover, we cut short **16** by truncation of the N-terminal dipeptidic LP sequence and the C-terminal GGSG sequence (ESI, Fig. S68[†]). Gratifyingly, the K_D value of the truncated peptide to TEAD4 is 70.1 nM, comparable to **16** (Supplementary Fig. S79[†]). Note that the linear version of **16** provides a K_D value of 6.5 μ M, 102 times higher than that of **16**, highlighting the contribution of the bicyclic scaffold to the peptide binding affinity.

Finally, we evaluated the bioactivity of **16** at the cellular level. To confirm the ability of **16** to capture endogenous TEAD4, a biotin was conjugated to the N-terminus of **16** for the streptavidin pull-down assay. After co-incubation with AGS cell lysates, the sample treated with **16-Biotin** was captured by

streptavidin-coated beads and showed a distinct TEAD4 band on SDS-PAGE (Fig. 4B). In contrast, the biotin-treated sample does not show a TEAD4 band. We then measured the inhibitory activity of **16** on AGS cells. Despite the presence of PDPA (a well-known nanocarrier for intracellular peptide delivery),⁵⁴ **16** showed little inhibitory inhibition on AGS cells at 10 μ M (ESI, Fig. S92[†]). Given that TEAD4 is located in the nucleus, a positively charged TAT or NLS (Nuclear Localization Sequence) tag was conjugated to the N-terminus of **16** (Fig. 4A). Gratifyingly, **16-TAT** and **16-NLS** exhibited cellular inhibitory activity with EC_{50} values of 13.8 μ M and 8.3 μ M (Fig. 4C). As a control, **TAT** and **NLS** that were not conjugated with **16** exhibit little cytotoxicity to AGS cells, indicating the contribution of **16** to the observed cellular inhibitory activity of **16-TAT** and **16-NLS**.

Conclusions

To summarize, we describe a ligase-based macrocyclization strategy for the construction of phage-displayed peptide macrocycle libraries, named SrtA-mediated peptide ligation and one-pot cyclization (SPLOC). The key to this strategy is to mine the tolerance of sortase to unnatural amino acids at the X site of the LPXTG motif. The electrophilic chloroacetyl group on the side chain of the X residue allows intramolecular cyclization with the cysteine residue to form peptide macrocycles. The SPLOC strategy is combined with phage display to generate a new type of genetically encoded macrocyclic peptide library for peptide ligand discovery. Using TEAD4 as a model target, we identified a potent bicyclic peptide with a K_D value of 63.9 nM to TEAD4. This bicyclic peptide can effectively block the TEAD4·YAP interaction and exhibit cellular inhibitory activity. Employing the unnatural promiscuity of peptide ligases to generate peptide macrocycles represents a new direction for the construction of genetically encoded peptide libraries.

Data availability

All experimental data that support the results of this study can be found in this article or in the ESI.[†]

Author contributions

The idea of the study was designed by G.-M. Fang. The system of sortase-based phage display was established by Y.-N. Zhang. The sortase-mediated peptide ligation and cyclization was performed by Y.-N. Zhang. The procedure for phage display was established by Y.-N. Zhang and X.-C. Wan. TEAD4-targeting cyclic peptides were synthesized and analysed by Y.-N. Zhang, X.-C. Wan, Y. Chen, Z.-H. Cui, F.-H. Zheng, H. Zhang. The idea of the cellular activity was designed by Z. Zhou. The activity of the peptides was measured by Y. Tang. The manuscript was written and checked by G.-M. Fang and Y.-N. Zhang.

Conflicts of interest

The authors declare that there are no conflicts of interest.




Fig. 4 TAT or NLS-modification of the bicyclic peptide **16**. (A) Structure of the peptides that contain the N-terminal TAT or NLS tag. (B) Streptavidin–biotin pull-down of endogenous TEAD4 by **16-Biotin** (IB: immunoblotting, IP: immunoprecipitation). (C) Cellular inhibitory activity of the peptides to AGS cells.



Acknowledgements

This work was supported by the National Natural Science Foundation of China (no. 22077002 and 21807001). For the construction of the M13 phage library, ER 2738 cells and the M13KE phage vector were obtained from NEB Ltd. For the construction of the phagemid system, the M13KO7 helper phage, TG1 cells and pCantab 5E vector were obtained from NB Biolab (Chengdu, China). The TEAD4 coding sequence was inserted into the pET-28a vector by the laboratory of Zhaocai Zhou, Fudan University, Shanghai, China. For cellular activity, AGS cells were obtained from the cell library of Chinese Academy of Sciences (Shanghai, China). We thank the staff for providing technical support with using the facility of Institute of Health Sciences & Technology, Anhui University.

References

- 1 A. Zorzi, K. Deyle and C. Heinis, *Curr. Opin. Chem. Biol.*, 2017, **38**, 24–29.
- 2 A. A. Vinogradov, Y. Yin and H. Suga, *J. Am. Chem. Soc.*, 2019, **141**, 4167–4181.
- 3 D. S. Nielsen, N. E. Shepherd, W. Xu, A. J. Lucke, M. J. Stoermer and D. P. Fairlie, *Chem. Rev.*, 2017, **117**, 8094–8128.
- 4 E. A. Villar, D. Beglov, S. Chennamadhavuni, J. A. Porco Jr, D. Kozakov, S. Vajda and A. Whitty, *Nat. Chem. Biol.*, 2014, **10**, 723–731.
- 5 E. Valeur, S. M. Guéret, H. Adihou, R. Gopalakrishnan, M. Lemurell, H. Waldmann, T. N. Grossmann and A. T. Plowright, *Angew. Chem., Int. Ed.*, 2017, **56**, 10294–10323.
- 6 S. Dong, J.-S. Zheng, Y. Li, H. Wang, G. Chen, Y. Chen, G. Fang, J. Guo, C. He, H. Hu, X. Li, Y. Li, Z. Li, M. Pan, S. Tang, C. Tian, P. Wang, B. Wu, C. Wu, J. Zhao and L. Liu, *Sci. China: Chem.*, 2024, **67**, 1060–1096.
- 7 D. Neri and R. A. Lerner, *Annu. Rev. Biochem.*, 2018, **87**, 479–502.
- 8 K. T. Mortensen, T. J. Osberger, T. A. King, H. F. Sore and D. R. Spring, *Chem. Rev.*, 2019, **119**, 10288–10317.
- 9 C. Sohrabi, A. Foster and A. Tavassoli, *Nat. Rev. Chem.*, 2020, **4**, 90–101.
- 10 R. C. Ladner, *Trends Biotechnol.*, 1995, **13**, 426–430.
- 11 R. C. Ladner, A. K. Sato, J. Gorzelany and M. de Souza, *Drug Discovery Today*, 2004, **9**, 525–529.
- 12 C. Chen, I. R. Rebollo, S. A. Buth, J. Morales-Sanfrutos, J. Touati, P. G. Leiman and C. Heinis, *J. Am. Chem. Soc.*, 2013, **135**, 6562–6569.
- 13 S. Lu, Y. Wu, J. Li, X. Meng, C. Hu, Y. Zhao and C. Wu, *J. Am. Chem. Soc.*, 2020, **142**, 16285–16291.
- 14 H. Dong, J. Li, H. Liu, S. Lu, J. Wu, Y. Zhang, Y. Yin, Y. Zhao and C. Wu, *J. Am. Chem. Soc.*, 2022, **144**, 5116–5125.
- 15 S. Lu, S. Fan, S. Xiao, J. Li, S. Zhang, Y. Wu, C. Kong, J. Zhuang, H. Liu, Y. Zhao and C. Wu, *J. Am. Chem. Soc.*, 2023, **145**, 1964–1972.
- 16 J. Li, H. Liu, S. Xiao, S. Fan, X. Cheng and C. Wu, *J. Am. Chem. Soc.*, 2023, **145**, 28264–28275.
- 17 H.-K. Cui, Y. Guo, Y. He, F.-L. Wang, H.-N. Chang, Y.-J. Wang, F.-M. Wu, C.-L. Tian and L. Liu, *Angew. Chem., Int. Ed.*, 2013, **52**, 9558–9562.
- 18 Y. Guo, D.-M. Sun, F.-L. Wang, Y. He, L. Liu and C.-L. Tian, *Angew. Chem., Int. Ed.*, 2015, **54**, 14276–14281.
- 19 C. Zuo, W.-W. Shi, X.-X. Chen, M. Glatz, B. Riedl, I. Flamme, E. Pook, J. Wang, G.-M. Fang, D. Bierer and L. Liu, *Sci. China: Chem.*, 2019, **62**, 1371–1378.
- 20 A. Angelini and C. Heinis, *Curr. Opin. Chem. Biol.*, 2011, **15**, 355–361.
- 21 R. Derda and S. Ng, *Curr. Opin. Chem. Biol.*, 2019, **50**, 128–137.
- 22 S. E. Iskandar, V. A. Haberman and A. A. Bowers, *ACS Comb. Sci.*, 2020, **22**, 712–733.
- 23 C. Heinis, T. Rutherford, S. Freund and G. Winter, *Nat. Chem. Biol.*, 2009, **5**, 502–507.
- 24 S. Kalhor-Monfared, M. R. Jafari, J. T. Patterson, P. I. Kitov, J. J. Dwyer, J. J. Nuss and R. Derda, *Chem. Sci.*, 2016, **7**, 3785–3790.
- 25 K. F. Tjhung, P. I. Kitov, S. Ng, E. N. Kitova, L. Deng, J. S. Klassen and R. Derda, *J. Am. Chem. Soc.*, 2016, **138**, 32–35.
- 26 S. S. Kale, C. Villequey, X.-D. Kong, A. Zori, K. Deyle and C. Heinis, *Nat. Chem.*, 2018, **10**, 715–723.
- 27 Y. Yin, Q. Fei, W. Liu, Z. Li, H. Suga and C. Wu, *Angew. Chem., Int. Ed.*, 2019, **58**, 4880–4885.
- 28 X.-D. Kong, J. Moriya, V. Carle, F. Pojer, L. A. Abriata, K. Deyle and C. Heinis, *Nat. Biomed. Eng.*, 2020, **4**, 560–571.
- 29 X. Zheng, Z. Li, W. Gao, X. Meng, X. Li, L. Y. P. Luk, Y. Zhao, Y.-H. Tsai and C. Wu, *J. Am. Chem. Soc.*, 2020, **142**, 5097–5103.
- 30 A. I. Ekanayake, L. Sobze, P. Kelich, J. Youk, N. J. Bennett, R. Mukherjee, A. Bhardwaj, F. Wuest, L. Vukovic and R. Derda, *J. Am. Chem. Soc.*, 2021, **143**, 5497–5507.
- 31 J. Wong, R. Mukherjee, O. Bilyk, J. Miao, V. T. Guzman, M. Miskoizie, Y.-S. Lin, A. Henninot, J. J. Dwyer, S. Kharchenko, A. Iampolska, D. Volochnyuk, L. M. Postovit and R. Derda, *Chem. Sci.*, 2021, **12**, 9694–9703.
- 32 M. Zheng, F. Haeffner and J. Gao, *Chem. Sci.*, 2022, **13**, 8349–8354.
- 33 M. Zheng, F.-J. Chen, K. Li, R. M. Reja, F. Haeffner and J. Gao, *J. Am. Chem. Soc.*, 2022, **144**, 15885–15893.
- 34 T. R. Oppewal, I. D. Jansen, J. Hekelaar and C. Mayer, *J. Am. Chem. Soc.*, 2022, **144**, 3644–3652.
- 35 F.-J. Chen, N. Pinnette, F. Yang and J. Gao, *Angew. Chem., Int. Ed.*, 2023, **62**, e202306813.
- 36 J. He, P. Ghosh and C. Nitsche, *Chem. Sci.*, 2024, **15**, 2300–2322.
- 37 X. S. Wang, P.-H. C. Chen, J. T. Hampton, J. M. Tharp, C. A. Reed, S. K. Das, D.-S. Wang, H. S. Hayatshahi, Y. Shen, J. Liu and W. Liu, *Angew. Chem., Int. Ed.*, 2019, **58**, 15904–15909.
- 38 B. Oller-Salvia and J. W. Chin, *Angew. Chem., Int. Ed.*, 2019, **58**, 10844–10848.
- 39 J. M. Tharp, J. T. Hampton, C. A. Reed, A. Ehnbohm, P. C. Chen, J. S. Morse, Y. Kurra, L. M. Pe-rez, S. Xu and W. R. Liu, *Nat. Commun.*, 2020, **11**, 1392.



- 40 A. E. Owens, J. A. Iannuzzelli, Y. Gu and R. Fasan, *ACS Cent. Sci.*, 2020, **6**, 368–381.
- 41 T. Navaratna, L. Atangcho, M. Mahajan, V. Subramanian, M. Case, A. Min, D. Tresnak and G. M. Thurber, *J. Am. Chem. Soc.*, 2020, **142**, 1882–1894.
- 42 J. T. Hampton, T. J. Lalonde, J. M. Tharp, Y. Kurra, Y. R. Alugubelli, C. M. Roundy, G. L. Hamer, S. Xu and W. R. Liu, *ACS Chem. Biol.*, 2022, **17**, 2911–2922.
- 43 M. A. Fischbach and C. T. Walsh, *Chem. Rev.*, 2006, **106**, 3468–3496.
- 44 L. M. Repka, J. R. Chekan, S. K. Nair and W. A. van der Donk, *Chem. Rev.*, 2017, **117**, 5457–5520.
- 45 J. H. Urban, M. A. Moosmeier, T. Aumüller, M. Thein, T. Bosma, R. Rink, K. Groth, M. Zully, K. Siegers, K. Tissot, G. N. Moll and J. Prassler, *Nat. Commun.*, 2017, **8**, 1500.
- 46 X. Yang, K. R. Lennard, C. He, M. C. Walker, A. T. Ball, C. Doigneaux, A. Tavassoli and W. A. van der Donk, *Nat. Chem. Biol.*, 2018, **14**, 375–380.
- 47 M. C. Fleming, M. M. Bowler, R. Park, K. I. Popov and A. A. Bowers, *J. Am. Chem. Soc.*, 2023, **145**, 10445–10450.
- 48 A. A. Vinogradov, M. Shimomura, Y. Goto, T. Ozaki, S. Asamizu, Y. Sugai, H. Suga and H. Onaka, *Nat. Commun.*, 2020, **11**, 2272.
- 49 M. Schmidt, A. Toplak, P. JIM Quaedflieg and T. Nuijens, *Curr. Opin. Chem. Biol.*, 2017, **38**, 1–7.
- 50 S. K. Mazmanian, G. Liu, H. Ton-That and O. Schneewind, *Science*, 1999, **285**, 760–763.
- 51 H. Mao, S. A. Hart, A. Schink and B. A. Pollok, *J. Am. Chem. Soc.*, 2004, **126**, 2670–2671.
- 52 I. Chen, B. M. Dorr and D. R. Liu, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 11399–11404.
- 53 M. W.-L. Popp and H. L. Ploegh, *Angew. Chem., Int. Ed.*, 2011, **50**, 5024–5232.
- 54 H. Ai, G.-C. Chu, Q. Gong, Z.-B. Tong, Z. Deng, X. Liu, F. Yang, Z. Xu, J.-B. Li, C. Tian and L. Liu, *J. Am. Chem. Soc.*, 2022, **144**, 18329–18337.
- 55 Y. Goto and H. Suga, *Acc. Chem. Res.*, 2021, **54**, 3604–3617.
- 56 S. Jiao, H. Wang, Z. Shi, A. Dong, W. Zhang, X. Song, F. He, Y. Wang, Z. Zhang, W. Wang, X. Wang, T. Guo, P. Li, Y. Zhao, H. Ji, L. Zhang and Z. Zhou, *Cancer Cell*, 2014, **25**, 166–180.
- 57 D. J. Williamson, M. A. Fascione, M. E. Webb and W. B. Turnbull, *Angew. Chem., Int. Ed.*, 2012, **51**, 9377–9380.
- 58 Y.-M. Li, Y.-T. Li, M. Pan, X.-Q. Kong, Y.-C. Huang, Z.-Y. Hong and L. Liu, *Angew. Chem., Int. Ed.*, 2014, **53**, 2198–2202.
- 59 C. Zuo, R. Ding, X. Wu, Y. Wang, G.-C. Chu, L.-J. Liang, H. Ai, Z.-B. Tong, J. Mao, Q. Zheng, T. Wang, Z. Li, L. Liu and D. Sun, *Angew. Chem., Int. Ed.*, 2022, **61**, e202201887.
- 60 H. E. Morgan, W. B. Turnbull and M. E. Webb, *Chem. Soc. Rev.*, 2022, **51**, 4121–4145.
- 61 E. C. B. Johnson and S. B. H. Kent, *J. Am. Chem. Soc.*, 2006, **128**, 6640–6646.
- 62 Y. Wu, A. Zori, J. Williams and C. Heinis, *Chem. Commun.*, 2020, **56**, 2917–2920.
- 63 S. Ng, M. R. Jafari, W. L. Matochko and R. Derda, *ACS Chem. Biol.*, 2012, **7**, 1482–1487.
- 64 G. T. Hess, J. J. Cragolini, M. W. Popp, M. K. Allen, S. K. Dougan, E. Spooner, H. L. Ploegh, A. M. Belcher and C. P. Guimaraes, *Bioconjugate Chem.*, 2012, **23**, 1478–1487.
- 65 Y. Ding, H. Chen, J. Li, L. Huang, G. Song, Z. Xi, X. Hua, G. Gonzalez-Sapienza, B. D. Hammock and M. Wang, *Anal. Chem.*, 2021, **93**, 11800–11808.
- 66 G. T. Hess, C. P. Guimaraes, E. Spooner, H. L. Ploegh and A. M. Belcher, *ACS Synth. Biol.*, 2013, **2**, 490–496.
- 67 H. D. Wilson, X. Li, H. Peng and C. Rader, *J. Mol. Biol.*, 2018, **430**, 4387–4400.
- 68 T. Teschke, B. Geltinger, A. Dose, C. Freund and D. Schwarzer, *ACS Chem. Biol.*, 2013, **8**, 1692–1697.
- 69 H. Adihou, R. Gopalakrishnan, T. Förster, S. M. Guéret, R. Gasper, S. Geschwindner, C. C. Garcia, H. Karatas, A. V. Pobbati, M. Vazquez-Chantada, P. Davey, C. M. Wassvik, J. K. S. Pang, B. S. Soh, W. Hong, E. Chiarparin, D. Schade, A. T. Plowright, E. Valeur, M. Lemurell, T. N. Grossmann and H. Waldmann, *Nat. Commun.*, 2020, **11**, 5425.
- 70 O. S. Tokareva, K. Li, T. L. Travaline, T. M. Thomson, J.-M. Swiecicki, M. Moussa, J. D. Ramirez, S. Litchman, G. L. Verdine and J. H. McGee, *Nat. Commun.*, 2023, **14**, 6992.

